Merck to Halt Hep C Combo Trials

Oct 02, 2017

Merck announced it will discontinue developing an experimental drug combination for chronic hepatitis C, after reviewing mid-stage trial data of the treatments.

Merck made the decision about the new combo treatments (MK-3682B and MK-3682C) after reviewing their effectiveness and considering the crowded Hep C market.

The drugmaker says it will continue to study its approved treatment, Zepatier, to understand even more about its role in treating chronic hepatitis C infection.

Read the press release


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments